Chief Technology Officer
CurrentLaunched the commercialization of long, complex oligos through our Fully Enzymatic Synthesis (FES) technology and established technology roadmaps to continue the advancement of synthesis performance and capacity growth, overseeing R&D efforts and manufacturing transfer. Our offerings fills the frustrating gap of getting DNA at the sequence complexity.